Ascentage Pharma Reports Revenue Surge in 2024 Ascentage Pharma has reported a significant revenue increase of 342% for 2024, reaching $134.3 million, largely driven by a $100 million payment from Takeda and increased sales of olverembatinib. Despite higher R&D expenses, the company reduced its annual loss by 56%, signaling improved financial performance.1